학술논문
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study
Document Type
Article
Author
Source
In: Annals of the Rheumatic Diseases . (Annals of the Rheumatic Diseases, October 2017, 76(10):1679-1687)
Subject
Language
English
ISSN
14682060
00034967
00034967